Back
Top 0.7%
23.2%
Top 3%
8.2%
Top 2%
8.2%
Top 0.4%
6.7%
Top 41%
6.2%
Top 81%
5.3%
#1
5.3%
Top 3%
4.4%
Top 2%
4.0%
Top 2%
2.0%
Top 1%
2.0%
Top 3%
2.0%
Top 2%
2.0%
Top 3%
1.6%
Top 2%
1.6%
Top 7%
1.6%
Top 10%
1.2%
Top 5%
1.0%
Top 3%
1.0%
Top 23%
1.0%
Top 9%
0.7%
Top 10%
0.7%
Top 6%
0.7%
Adaptive Responses to PARP Inhibition Predict Response to Olaparib and Durvalumab: Multi-omic Analysis of Serial Biopsies in the AMTEC Trial
2024-08-30
oncology
Title + abstract only
View on medRxiv
Show abstract
In syngeneic murine breast cancer models, poly(ADP-ribose) polymerase inhibitor (PARPi) and anti-PD-L1 combinations induce deep, sustained responses independent of BRCA1 or BRCA2 mutation (BRCAm) status. We therefore investigated this combination in the AMTEC clinical trial, in which a one-month olaparib run-in was followed by combined olaparib and durvalumab in participants with non-BRCAm metastatic triple negative breast cancer. To characterize adaptive responses to olaparib monotherapy, paire...
Predicted journal destinations
1
Nature Communications
483 training papers
2
Cancers
57 training papers
3
eLife
262 training papers
4
Clinical Cancer Research
22 training papers
5
Scientific Reports
701 training papers
6
PLOS ONE
1737 training papers
7
Cell Reports
25 training papers
8
Frontiers in Oncology
34 training papers
9
Proceedings of the National Academy of Sciences
100 training papers
10
iScience
74 training papers
11
Journal of Clinical Investigation
50 training papers
12
British Journal of Cancer
22 training papers
13
BMC Cancer
21 training papers
14
Cancer Medicine
17 training papers
15
International Journal of Molecular Sciences
39 training papers
16
Frontiers in Immunology
140 training papers
17
PLOS Computational Biology
141 training papers
18
Cell Reports Medicine
49 training papers
19
Communications Biology
36 training papers
20
JAMA Network Open
125 training papers
21
Nature
58 training papers
22
Nature Genetics
72 training papers
23
Communications Medicine
63 training papers